News
ARDX
4.805
+3.56%
0.165
Weekly Report: what happened at ARDX last week (1216-1220)?
Weekly Report · 3d ago
Ardelyx: A Small Bet Its Latest Setback Will Be Temporary
Seeking Alpha · 6d ago
Biotech Alert: Searches spiking for these stocks today
TipRanks · 6d ago
Ardelyx (ARDX) Sees Its Depressed Stock Turning Around
TipRanks · 12/16 10:30
Weekly Report: what happened at ARDX last week (1209-1213)?
Weekly Report · 12/16 10:29
Weekly Report: what happened at ARDX last week (1202-1206)?
Weekly Report · 12/09 10:27
Potential Growth for Ardelyx’s Ibsrela Amidst Market Volatility
TipRanks · 12/06 05:56
ARDELYX INC <ARDX.O>: LEERINK PARTNERS RAISES TARGET PRICE TO $12 FROM $11
Reuters · 12/04 11:52
Weekly Report: what happened at ARDX last week (1125-1129)?
Weekly Report · 12/02 10:28
Weekly Report: what happened at ARDX last week (1118-1122)?
Weekly Report · 11/25 10:22
Ardelyx Lost The Lawsuit, But The Kidney PATIENT Act Will Save It
Seeking Alpha · 11/24 11:36
Insider Sale: Chief Medical Officer of $ARDX (ARDX) Sells 7,366 Shares
Barchart · 11/23 04:00
Insider Sale: See Remarks of $ARDX (ARDX) Sells 7,046 Shares
Barchart · 11/23 03:44
Ardelyx Appoints Joseph Reilly as Principal Accounting Officer
TipRanks · 11/18 21:35
Weekly Report: what happened at ARDX last week (1111-1115)?
Weekly Report · 11/18 10:21
Friday 11/15 Insider Buying Report: ARDX, PAL
NASDAQ · 11/15 18:58
Ardelyx's Medicare Setback Casts Doubt On Long-Term Viability
Seeking Alpha · 11/14 14:34
Appleseed Fund 2024 Annual  Shareholder Letter
Seeking Alpha · 11/13 15:35
Ardelyx down as H.C. Wainwright downgrades rating on anticipated Xphozah sales drop
Seeking Alpha · 11/11 19:43
Ardelyx Price Target Announced at $5.50/Share by HC Wainwright & Co.
Dow Jones · 11/11 12:28
More
Webull provides a variety of real-time ARDX stock news. You can receive the latest news about Ardelyx through multiple platforms. This information may help you make smarter investment decisions.
About ARDX
Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.